Anticoagulants: Updates on idarucizumab
نویسندگان
چکیده
منابع مشابه
Anticoagulants: newer ones, mechanisms, and perioperative updates.
With a growing number of new anticoagulant/antiplatelet agents being developed, it is likely that an increasing number of patients taking these drugs will present for surgery and other procedures. A familiarity with mechanisms of action and drug interactions helps to maintain optimal patient safety in the perioperative period. Furthermore, it is crucial for anesthesiologists to remain current o...
متن کاملReversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab
Novel oral anticoagulants (NOACs) are increasingly used in clinical practice, but lack of commercially available reversal agents is a major barrier for mainstream use of these therapies. Specific antidotes to NOACs are under development. Idarucizumab (aDabi-Fab, BI 655075) is a novel humanized mouse monoclonal antibody that binds dabigatran and reverses its anticoagulant effect. In a recent Pha...
متن کاملAnaphylaxis after Idarucizumab Infusion
Dear Editor, Dabigatran etexilate is commonly used for the prevention of stroke in patients with nonvalvular atrial fibrillation, and is as effective as and safer than warfarin.1 However, there is no reversal agent despite serious outcomes of bleeding complication,2 with hemodialysis being the only reliable option. Idarucizumab has recently been developed as a genuine reversal agent of dabigatr...
متن کاملIdarucizumab for Dabigatran Reversal.
BACKGROUND Specific reversal agents for non-vitamin K antagonist oral anticoagulants are lacking. Idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran. METHODS We undertook this prospective cohort study to determine the safety of 5 g of intravenous idarucizumab and its capacity to reverse the anticoagulant effects of dabigatran in patients who h...
متن کاملUpper gastrointestinal endoscopy in emergency setting for patients receiving oral anticoagulants – practice updates
Anticoagulants are frequently used medications in diverse cardiovascular diseases. Their uses highly increase the risk of bleeding from upper and lower gastrointestinal sources, whether there is a classic vitamin K antagonist or a novel oral anticoagulant. Their interruption can promote procoagulation status with different thromboembolic accidents. Discontinuation of oral anticoagulants before ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Dental Journal
سال: 2017
ISSN: 0007-0610,1476-5373
DOI: 10.1038/sj.bdj.2017.95